Novo Nordisk Receives FDA Approval for Sogroya® in Children with Turner Syndrome

11/20/2026
Impact: 65
Healthcare

The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) to treat growth failure in children aged 2.5 years and older with Turner syndrome. The company said it is the first and only once-weekly growth hormone option for this group, potentially reducing injection frequency compared with daily therapies. Sogroya is now approved for five growth-related disorders; the article reported no financial figures or stock-price impact.

AI summary, not financial advice

Share: